Eurobio Scientific H1 revenue rises 5% to EUR 84.5 million

• Eurobio Scientific reported H1 2026 revenue of EUR 84.5 million, up 4.7% from EUR 80.7 million a year earlier.
• On a comparable pro forma basis excluding acquisition effects, revenue was flat; Voden Medical Instruments’ life sciences unit contributed EUR 3.8 million.
• Proprietary products revenue rose 10% to EUR 31.3 million, representing about 37% of group sales; like-for-like growth was 7%.
• Distribution products revenue increased 2% to EUR 53.2 million; like-for-like revenue fell 5% amid the end of One Lambda tenders.
• Seegene-related revenue climbed 12% to EUR 25.6 million; Seegene plans to sell direct in France when the distribution contract ends Dec. 31, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eurobio Scientific SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607281145OMX_____CNEWS_FR_GNW1001254822_fr) on July 28, 2026, and is solely responsible for the information contained therein.